Auriga Upgrades Omnicell (OMCL) to Buy
More News related to OMCL
- Omnicell Introduces Anywhere RN for Remote Medication Management to Improve Clinician Efficiency in Hospitals
- Omnicell Introduces Anywhere RN for Remote Medication Management to Improve Clinician Efficiency in Hospitals
- Omnicell to Present at Piper Jaffray Healthcare Conference
- Omnicell (OMCL) Reports In-Line Q4
- Omnicell Announces Third Quarter 2009 Results
Auriga upgrades Omnicell (Nasdaq: OMCL) from Hold to Buy. Price target increased from $8 to $11.
Auriga analyst says, "Though hospitals continue to defer capital spending decisions in a tight credit market, OMCL's backlog guidance is $110 million, gives us comfort that results will approach the high end of its range."
Omnicell, Inc. is a provider of medication control and patient safety solutions for acute care health facilities.
Related Categories
UpgradesStocks Mentioned
-0.36Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
